Saturday 17 October 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%

Follow DXCM

Alert me

Market cap: $33.1B
P/E: 33.2×
Fwd P/E: 29.8×
Dividend yield: —
F-score: 8/9
Altman Z: 6.43
Beneish M: −2.70
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Auditor change Feb 12, 2026

All filings →

Insider Decisions trades per month

Total buys 1.00

Total sells 12.62

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	3	—	—	1	1	1	3	3	4	4	4	—

Insider Ownership 2.90%

Capital & Financial Ratios $m

Market Cap 33,100.00

Revenue 4,969.20

Net Income 999.70

Free Cash Flow 1,405.00

Net Debt (704.20)

Current Ratio 1.73

Debt/Equity 0.47

P/E ratio 33.23

Fwd P/E 29.80

P/S ratio 6.62

P/B ratio 12.55

Past 5Y EPS Growth 10.56%

This Y EPS Growth 27.73%

Next Y EPS Growth 17.08%

Next Y revenue growth 12.18%

Next 5Y EPS Growth 21.34%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 8.93%

10-year low 10-year high

P/S against its own 10 years 10.91%

10-year low 10-year high

P/B against its own 10 years 15.92%

10-year low 10-year high

EV/Sales against its own 10 years 12.24%

10-year low 10-year high

EV/FCF against its own 10 years 15.89%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	2,724	2,579	1,999	1,947
Receivables	974	1,006	1,216	1,258
Inventory	560	543	629	726
Other	—	—	—	—
	4,426	4,301	4,033	4,087

	2023	2024	2025	Q'26
Payables	1,346	1,585	1,944	2,192
ST’ Debt	—	—	—	—
Other	—	8	8	9
	1,556	2,932	2,143	2,358

Compound Annual Growth %

	10y	5y	3y
Sales	27.77%	19.33%	17.01%
Cash Flow	40.23%	24.81%	29.10%
Earnings	0.00%	8.75%	34.83%
Book Value	28.64%	8.50%	8.81%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,192	1,308	—	—	—
’25	1,036	1,157	1,209	1,260	4,662
’24	921	1,004	994	1,114	4,033
’23	742	871	975	1,035	3,622
’22	629	696	770	815	2,910
’21	505	595	650	698	2,449
’20	405	452	501	569	1,927

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	526	269	—	—	—
’25	184	303	660	294	1,441
’24	209	279	200	301	990
’23	155	190	269	134	749
’22	71	173	293	133	670
’21	28	62	247	106	443
’20	2	154	148	172	476

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	449	185	—	—	—
’25	97	209	579	192	1,077
’24	152	213	88	177	631
’23	81	131	219	81	512
’22	(33)	84	185	69	305
’21	(72)	(40)	139	2,692	2,720
’20	(31)	96	100	112	277

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.51	0.64	—	—	—
’25	0.27	0.45	0.70	0.68	2.09
’24	0.36	0.35	0.34	0.38	1.42
’23	0.12	0.28	0.29	0.62	1.30
’22	0.23	0.12	0.24	0.22	0.82
’21	0.10	0.16	0.18	(0.05)	0.39
’20	0.05	0.12	0.18	0.87	1.27

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	11.98	10.66	12.76	26.86	45.52	79.61	66.89	74.75	62.34	54.11	Analyst estimates 2026–2028 Powerpack
	High	24.10	22.20	38.04	58.00	114.06	164.86	134.77	139.55	142.00	93.25
People
People	Employees	2,300	2,990	2,800	3,900	6,400	7,000	7,600	9,600	10,300	11,000
	Revenue/emp, $m	0.25	0.24	0.37	0.38	0.30	0.35	0.38	0.38	0.39	0.42
Income, $m
Income, $m	Revenue	573	719	1,032	1,476	1,927	2,449	2,910	3,622	4,033	4,662
	Gross margin, %	66.00	68.49	64.36	63.11	66.44	68.63	64.72	63.19	60.46	60.10
	EBT	(65)	(49)	(126)	104	298	257	391	710	709	1,088
	EBT margin, %	(11.32)	(6.76)	(12.26)	7.06	15.46	10.49	13.43	19.61	17.58	23.35
	Net income	(66)	(50)	(127)	101	550	217	341	542	576	836
	Depreciation	15	16	29	49	67	102	156	186	218	252
Per share, $
Per share, $	Revenue	1.71	2.08	2.92	4.05	5.10	6.33	7.47	9.38	10.25	11.95
	Earnings	(0.19)	(0.14)	(0.36)	0.28	1.31	0.56	0.88	1.40	1.46	2.14
	Cash flow	0.17	0.27	0.35	0.86	1.26	1.14	1.72	1.94	2.51	3.69
	Capex	(0.17)	(0.19)	(0.19)	(0.49)	(0.53)	5.89	(0.94)	(0.61)	(0.91)	(0.93)
	Free cash flow	0.00	0.08	0.16	0.37	0.73	7.03	0.78	1.33	1.60	2.76
	Book value	0.85	1.21	1.88	2.42	4.84	5.28	5.47	5.36	5.34	7.04
	Shares, m	334	345	353	364	378	387	389	386	394	390
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	200.70	71.65	281.07	130.38	87.30	52.90	30.87
	P/S	8.49	6.97	10.24	13.50	18.11	21.21	15.35	13.12	7.59	5.56
	P/B	17.16	11.93	15.93	22.58	19.10	25.43	20.96	22.97	14.56	9.43
	EV/Sales	8.28	6.66	9.88	13.19	17.58	20.92	15.19	13.25	7.45	5.56
	EV/FCF	9,494.53	184.08	181.69	144.75	122.45	18.83	145.03	93.76	47.63	24.06
Cash, $m
Cash, $m	Operating cash flow	56	92	123	315	476	443	670	749	990	1,441
	Capex	(56)	(66)	(67)	(180)	(199)	2,277	(365)	(237)	(359)	(363)
	Free cash flow	1	26	56	135	277	2,720	305	512	631	1,077
Balance, $m
Balance, $m	Working capital	178	606	1,477	1,609	2,811	2,964	1,830	2,870	1,369	1,891
	Total debt	6	328	1,010	1,074	1,684	2,003	1,970	2,434	1,237	1,241
	Net debt	(118)	(221)	(375)	(460)	(1,023)	(728)	(486)	(290)	(1,342)	(758)
	Shareholders’ equity	284	419	663	883	1,827	2,042	2,132	2,069	2,103	2,746
Returns, %
Returns, %	ROA	(18.88)	(7.68)	(9.01)	4.69	16.44	4.70	6.61	9.29	9.04	13.04
	ROIC	(24.04)	(13.39)	(40.43)	21.03	23.31	12.65	14.86	21.00	49.33	28.66
	ROE	(25.98)	(14.28)	(23.48)	13.08	40.58	11.21	16.35	25.78	27.63	34.50

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BSX Boston Scientific Corporation	$64.0B	17.9×	17.8×	+7.53% (above 0%: growing)	+14.81% (above 0%: growing)	+13.29% (above 0%: growing)	70.71%	21.65%	Compare
EW Edwards Lifesciences Corporation	$50.8B	49.8×	30.7×	+13.63% (above 0%: growing)	−26.32% (below 0%: shrinking)	+142.84% (above 0%: growing)	77.46%	29.48%	Compare
DXCM DexCom, Inc.	$33.1B	33.2×	29.8×	+13.08% (above 0%: growing)	+41.30% (above 0%: growing)	−11.68% (below 0%: shrinking)	63.44%	24.33%
GEHC GE HealthCare Technologies Inc.	$31.8B	16.0×	14.4×	+5.75% (above 0%: growing)	+16.98% (above 0%: growing)	+750.00% (above 0%: growing)	41.17%	13.96%	Compare
PHG Koninklijke Philips N.V.	$24.9B	18.8×	11.2×	+2.94% (above 0%: growing)	+56.67% (above 0%: growing)	+49.74% (above 0%: growing)	49.31%	13.99%	Compare
STE STERIS plc	$21.9B	27.1×	23.6×	+7.30% (above 0%: growing)	+13.89% (above 0%: growing)	−14.36% (below 0%: shrinking)	45.84%	19.15%	Compare
ZBH Zimmer Biomet Holdings, Inc.	$18.0B	23.0×	17.7×	+4.80% (above 0%: growing)	+33.77% (above 0%: growing)	+13.05% (above 0%: growing)	70.81%	14.98%	Compare
PEN Penumbra, Inc.	$12.7B	78.4×	63.5×	+14.90% (above 0%: growing)	−24.79% (below 0%: shrinking)	+10.81% (above 0%: growing)	67.93%	10.52%	Compare
SNN Smith & Nephew SNATS, Inc.	$12.2B	35.4×	18.6×	+7.99% (above 0%: growing)	−14.23% (below 0%: shrinking)	+293.94% (above 0%: growing)	69.42%	0.00%	Compare
Median of peers	$23.4B	25.1×	18.2×	+7.42%	+14.35%	+31.52%	68.68%	14.48%

All 149 Medical Devices stocks →

DexCom, Inc. (DXCM) key facts

Strength: DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.
DexCom, Inc. (DXCM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, DXCM traded at $86.06, a market capitalization of $33.1 billion.
Return on equity was 34.5% and debt-to-equity 0.47.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 6.43 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.